Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H(2022) A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients Br J Cancer(in press) DOI 10.1038/s41416-022-01782-x, PubMed 35332267
Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H(2022) miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer Mol Oncol, 16(6), 1402-1419 DOI 10.1002/1878-0261.13184, PubMed 35064630
Tulipan AJ, Salberg UB, Hole KH, Vlatkovic L, Aarnes EK, Revheim ME, Lyng H, Seierstad T(2021) Amino acid transporter expression and 18F-FACBC uptake at PET in primary prostate cancer Am J Nucl Med Mol Imaging, 11(4), 250-259 PubMed 34513278
Heidi Lyng, Department of Radiation Biology, Institute for Cancer Research Norwegian Radium Hospital, Oslo University Hospital Phone +47 22 78 1478, e-mail: heidi.lyng@rr-research.no